BMS | ExChair - Scholarships @Awis_Houston | PHD @MDAndersonNews. Single cell genomics | Computational Biologist | Oncology. Crazy animal (-reptile) lover.

Joined March 2014
149 Photos and videos
Tapsi Kumar, PhD retweeted
Iza-Bren is very effective (not only in TNBC) but its profile is also very chemo-like. What’s the targeted contribution vs non-specific uptake? Iza-Bren half-life is ~1 day! What’s the correlation with EGFR expression? HER3 expression? Co-expression of both EGFR and HER3?
Impressive results from a phase 3 trial of Iza-Bren (anti-HER3/EGFR TOPO1 ADC) vs chemo in pretreated mTNBC, with improvement in PFS and OS. High rate of hematologic toxicities, including 5% febrile neutropenia. Phase 3 ongoing to confirm these results in a global population.
5
15
44
13,328
Tapsi Kumar, PhD retweeted
ビッグニュースが舞い込んできました! FDAでHER2陽性早期乳がんに対するエンハーツ(トラスツズマブ デルクステカン)が承認されました。 しかも、DB-11試験に基づく術前ハイリスク集団と、DB-05試験に基づく術後残存病変を有する集団の、両方に対して一気に適応されます。 同じように、日本での承認が待たれます。果たして術前も同時に承認されるのかがポイントになります。 fda.gov/drugs/resources-info…
Since the first phase 1 trial of T-DXd, it was clear that this drug could be transformative when taken to the curative setting. Today, the FDA approved T-DXd for the neoadjuvant or adjuvant treatment of HER2 eBC, marking a major advancement in the field. fda.gov/drugs/resources-info…
2
36
161
21,063
RT @NaturePortfolio: A study in Nature reveals that tumour microenvironments can be decomposed into spatially organized multicellular ecosy…
44
Tapsi Kumar, PhD retweeted
If you're serious about AI engineering (in 2026), then learn these 13 concepts: 1 How Vector Database Works → newsletter.systemdesign.one/… 2 How RAG Works → newsletter.systemdesign.one/… 3 Design Personal Chat Assistant → newsletter.systemdesign.one/… 4 LLM Concepts - A Deep Dive → newsletter.systemdesign.one/… 5 How to Design an AI Agent → newsletter.systemdesign.one/… 6 What is Reinforcement Learning → newsletter.systemdesign.one/… 7 LLM Evals 101 → newsletter.systemdesign.one/… 8 Context Engineering 101 → newsletter.systemdesign.one/… 9 AI Coding Workflow 101 → newsletter.systemdesign.one/… 10 Agentic Patterns, Simply Explained → newsletter.systemdesign.one/… 11 How AI Agents Work → newsletter.systemdesign.one/… 12 Multi-Agent Architectures, Clearly Explained → newsletter.systemdesign.one/… 13 How MCP Works → newsletter.systemdesign.one/… What else should make this list? === 👋 PS - Want my System Design Playbook (for Free)? Join my newsletter with 200K software engineers now: → newsletter.systemdesign.one/… === 💾 Save now & repost to help others learn AI engineering. 👤 Follow @systemdesignone turn on notifications.
32
252
967
59,599
Tapsi Kumar, PhD retweeted
🫁 MTAP deletions in NSCLC and EGFR. MTAP del in 10% (n=4926). In stage IV, 83% co-occurred with drivers; EGFR in 48%. Shorter time to osimertinib discontinuation (19.0 vs 24.9 mo; HR 1.8; p=0.01). No significant OS difference. Acquired MTAP del at resistance in 13%. Signal of activity with PRMT5 inhibition (BMS-986504). 📖 @JTOonline DOI 👉🏻 doi.org/10.1016/j.jtho.2025.… #CánCare #NSCLC #EGFR #biomarkers #targetedtherapy #lcsm
31
68
8,653
Tapsi Kumar, PhD retweeted
Claude can now teach your kids any school subject like a $100/hour private tutor from Khan Academy. For free. Here are 12 prompts that explain math, science, history, and English at any grade level in minutes: (Save this before it disappears)
46
355
2,097
258,908
Tapsi Kumar, PhD retweeted
What a time to be alive when I have to choose between attending Brian Wolpin’s talk on Daraxonrasib chemo in 1st line #PancreaticCancer OR @RevMedicines talk on their preclinical asset RM-055 that overcomes KRAS inhibitor resistance, BOTH at the exact same time! #AACR26
5
15
111
8,318
Tapsi Kumar, PhD retweeted
🔷Human Immune Cell Marker Guide 🩸🩸 #cellsignaling
69
276
12,748
Tapsi Kumar, PhD retweeted
Our new ADC review provides a different perspective on why ADC resistance occurs and how we can address it. advanced.onlinelibrary.wiley…

11
75
6,490
Tapsi Kumar, PhD retweeted
Cancer immunotherapy keeps revving up. Now onto a 3rd generation of T cell engagers sciencedirect.com/science/ar…
2
72
274
22,327
Tapsi Kumar, PhD retweeted
More than 430 abstracts on ADCs at #AACR26! ⬆️ Largely dominated by TOPO1i ADCs and bispecific ADCs ↗️ Dual payload ADCs are growing (36 abstracts) ↘️ Degrader Antibody Conjugates (DACs) not so much (12 abstracts) ⬇️ Limited novel ADC payload classes (<15 abstracts)
9
34
140
13,911
Tapsi Kumar, PhD retweeted
Apr 11
This 2 hour Stanford lecture shows exactly how Stanford trains it's engineers to build AI systems. It's more practical than every Claude tutorial & prompting threads you've seen. Bookmark & give it 2 hours, no matter what. It'll be the most productive thing you do this weekend.
158
1,904
13,646
1,667,464
Tapsi Kumar, PhD retweeted
Mar 28
Antibody Drug Conjugates ADCs toxicities are complex and need to be actively addressed #ELCC
1
20
64
5,570
Tapsi Kumar, PhD retweeted
Claude Chat vs Cowork vs Code Tab vs Code CLI — what's actually different? I used Claude Code to fact-checked every feature against official Anthropic docs and put together this comparison table.
2
5
19
2,257
Tapsi Kumar, PhD retweeted
BREAKING: AI can now analyze any stock like a Wall Street analyst (for free). Here are 10 insane Claude prompts that replace $2,000/month Bloomberg terminals (Save for later)
12
80
488
72,021
Tapsi Kumar, PhD retweeted
Wow! Cool--> #PrecisionMedicine in action 👉Individualized mRNA vaccines evoke durable T cell immunity in adjuvant Triple-negative breast cancer #TNBC @Nature @OncoAlert 👉Individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy 👉11/14 patients remained relapse-free for up to six years post-vaccination. nature.com/articles/s41586-0…
1
17
36
3,357
Tapsi Kumar, PhD retweeted
🚨BREAKING: Claude is insane for market research. I reverse-engineered how top consultants at McKinsey, Goldman Sachs, & JP Morgan use it. The difference is night and day. Here are 12 insane Claude Opus 4.6 prompts they don't want you to know (Save for later)
13
71
456
136,088
Tapsi Kumar, PhD retweeted
Important information to keep in mind. AI is an incredible tool to supplement your work but don’t use it as a substitute for thinking for yourself .. or you atrophy the parts of your brain used for thinking for yourself.
🧠 MIT recently completed the first brain-scan study on ChatGPT users—and the results are deeply revealing. Rather than boosting brain function, prolonged AI use may be dulling it. Over four months of cognitive data suggest we might be measuring productivity all wrong ⤵️ In MIT’s study, participants had their brains scanned while using ChatGPT. → 83.3% of users couldn’t recall a single sentence they’d written just minutes earlier. → In contrast, those writing without AI had no trouble remembering. Brain connectivity dropped sharply—from 79 to 42 points. → That’s a 47% drop in neural engagement. → The lowest cognitive performance among all user groups. Even after stopping ChatGPT use in later sessions, these users showed continued under-engagement. → Their performance remained lower than those who never used AI. → This suggests more than dependency—it’s cognitive weakening. Beyond the scans, educators flagged the writing itself. → Essays were technically solid, but often called “robotic,” “soulless,” and “lacking depth.” Here’s the paradox: → ChatGPT makes you 60% faster at completing tasks… → But it reduces the mental effort required for learning by 32%. The top-performing group? → Those who began without AI and added it later. → They retained the best memory, brain activity, and overall scores. Using ChatGPT can feel empowering—but it may quietly offload your thinking. → You gain speed, but lose engagement. → You get answers, but stop learning how to think. The takeaway isn’t to avoid AI—but to use it intentionally. → Use it to assist, not replace your mind. → Build cognitive strength—not dependency. MIT’s early study on AI and the brain lays out the stakes. The way we use these tools matters more than ever.
5
4
20
2,330
Tapsi Kumar, PhD retweeted
Top 5 Types of AI Agents!
9
64
281
9,234
Tapsi Kumar, PhD retweeted
Tumors resistant to one ADC can regain sensitivity to another ADC with a different payload. Our work shows payload choice—not just target expression—may extend clinical benefit in breast cancer. No evidence that sequential of FDA approved drugs are beneficial in the clinical setting. pubmed.ncbi.nlm.nih.gov/4159…
5
37
94
8,444